Blueprint Medicines Corp (BPMC) Stock
BPMC is no longer traded. Blueprint Medicines was acquired by Sanofi on July 18, 2025.
Each BPMC share was exchanged for $129.00 in cash plus a contingent value right of up to $6.00. Prices on this page are historical; the last trade was July 16, 2025 at $129.28.
Blueprint Medicines stock price history
BPMC final trading statistics
- Final close
- $129.28
- Final trading day
- Jul 16, 2025
- Market cap at delisting
- $8.35B
- Shares outstanding
- 64.58M
- Final 52-week range
- $73.04 – $129.65
- Avg. volume (final 3 mo.)
- 3,727,505
- All-time high (split-adj.)
- $129.36 · Jul 2025
- All-time low (split-adj.)
- $13.34 · Feb 2016
- Return since IPO
- +585.1%
- Beta
- 0.83
- Book value / share
- $5.30
- Price / book
- 24.40
Blueprint Medicines annual financials
| Fiscal year | Revenue | Net income | EPS |
|---|---|---|---|
| FY2024 | $508.82M | -$67.1M | -$1.08 |
| FY2023 | $249.38M | -$507.0M | -$8.36 |
| FY2022 | $204.04M | -$557.5M | -$9.35 |
| FY2021 | $180.08M | -$644.1M | -$10.92 |
| FY2020 | $793.74M | $313.9M | $5.24 |
Last five fiscal years reported before the delisting; fiscal year ending December. EPS is adjusted (non-GAAP) EPS as reported. Source: company filings via EODHD.
About Blueprint Medicines Corp
Blueprint Medicines Corporation, a precision therapy company, develops medicines for genomically defined cancers and blood disorders in the United States and internationally. The company is developing AYVAKIT for the treatment of systemic mastocytosis (SM) and gastrointestinal stromal tumors; BLU-263, an orally available, potent, and KIT inhibitor for the treatment of indolent SM, and other mast cell disorders. It is also developing GAVRETO for the treatment of RET fusion-positive non-small cell lung cancer, altered thyroid carcinoma, and medullary thyroid carcinoma; BLU-945 for the treatment of epidermal growth factor receptor driven non-small-cell lung carcinoma (NSCLC); and BLU-451 to treat NSCLC in patients with epidermal growth factor receptor gene (EGFR) exon 20 insertion mutations. In addition, the company is developing BLU-782, for the treatment of fibrodysplasia ossificans progressive; BLU- 222 to treat patients with cyclin E aberrant cancers; and BLU-852 for the treatment of advanced cancers. It has collaboration and license agreements with Clementia Pharmaceuticals, Inc.; Proteovant Therapeutics; CStone Pharmaceuticals; Genentech, Inc.; Hoffmann-La Roche Inc.; and Zai Lab (Shanghai) Co., Ltd. The company was formerly known as Hoyle Pharmaceuticals, Inc. and changed its name to Blueprint Medicines Corporation in June 2011. Blueprint Medicines Corporation was incorporated in 2008 and is headquartered in Cambridge, Massachusetts.
Blueprint Medicines stock FAQ
What happened to Blueprint Medicines stock?
Blueprint Medicines was acquired by Sanofi on July 18, 2025. Shareholders received $129.00 in cash plus a contingent value right of up to $6.00 for each share. BPMC stock stopped trading on the Nasdaq, with a final close of $129.28 on July 16, 2025.
What did Blueprint Medicines shareholders receive?
Each BPMC share was converted into $129.00 in cash plus a contingent value right of up to $6.00. The deal was valued at up to about $9.5 billion.
Is BPMC stock still trading?
No. BPMC was delisted from the Nasdaq on July 18, 2025 and no longer trades on a U.S. exchange.
What was the last price of BPMC stock?
BPMC closed at $129.28 on its final trading day, July 16, 2025, for a market value of about $8.35B.
What were Blueprint Medicines's revenue and earnings in its last full fiscal year?
Blueprint Medicines reported revenue of $508.82M and net income of -$67.1M in fiscal 2024, its last full year as a public company.
When did Blueprint Medicines go public?
Blueprint Medicines Corp stock began trading on April 30, 2015.